Roche Holding AG: Funding the Genentech Acquisition Financial Policy March 5‚ 2015 Morgan Ephriam Kristopher Kirkpatrick Jasmine White 1. Statement of the Problem In the case Roche Holding AG: Funding the Acquisition‚ Roche and Genentech are interested in an acquisition. Roche is acquiring about receiving all outstanding shares of Genentech. Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers‚ develops and provides diagnostic and therapeutic products
Premium Bond Discounted cash flow Finance
1) Why is Roche seeking to buy the 44% of Genentech it does not own? From Roche’s point of view‚ what are the advantages of owning 100% of Genentech? What are the risks? Roche is looking at this acquisition as a source of internal growth; the advantages are for research reasons‚ cutting cost creating a synergy by eliminating duplication of efforts and having easily access to Genentech’s free cash flow optimizing tax issues. Some analyst are concern that Genentech would lose its independence
Premium Stock market Stock Shareholder
Case Sustainability Initiative at Roche Table of Contents Introduction 3 Sustainable development: the triple bottom line 3 Economic‚ social and environmental responsibility 3 Social responsibility: the key elements 5 Corporate Responsibility Innovation at Roche 5 What is corporate responsibility? 5 Corporate responsibility according to the Roche corporate brochure 6 Target of responsibility as reflected in reported organizational structures‚ policies and practices. 7 Gaining competitive
Premium Sustainability Corporate social responsibility Business ethics
Advanced Corporate Finance Final Case: Roche 1 2 Reasons for Roche’s 100% ownership of Genentech Since Roche and Genentech both operate in the pharmaceutical industry‚ but still have their own specialty‚ they can benefit from a partnership. Roche owns a majority stake in Genentech since 1990 and since 2007‚ it owns 56% of Genentech. Genentech was founded in 1976‚ their focus lies on biotechnology in which they are the second largest firm of the world. Genentech had become an important
Premium Corporate finance Debt Finance
1 Roche 2013 results London‚ 30 January 2014 2 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’‚ ‘expects’‚ ‘anticipates’‚ ‘projects’‚ ‘intends’‚ ‘should’‚ ‘seeks’‚ ‘estimates’‚ ‘future’ or similar expressions or by discussion of‚ among other things‚ strategy‚ goals‚ plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking
Premium Cancer Oncology Tumor
controversial context. In 2010‚ pharmaceutical giant Roche received a shame award by the Swiss non-governmental organization Berne Declaration and Greenpeace for conducting clinical trials with organs taken from executed prisoners in China. The company respected local regulations and industry ethical standards. However‚ medical associations condemned organs from executed prisoners on moral grounds. Human rights organizations demanded that Roche ended its clinical trials in China immediately. Students
Premium Human rights Organ transplant Pharmaceutical industry
moment‚ Roche has a share of 65.9 %. The plan is to buy the rest of the 44.1 % of shares‚ so this case is clearly a complete acquisition. The merger of Roche is clearly a horizontal takeover. Both firms focus on pharmaceutical research‚ where Roche is mainly focused on pharmaceuticals and mdedical diagnoses. Genentech is primarily focused on devevloping products based on gene splicing or recombinant DNA for diseases such as cancer and aids. The reason for a complete takeover could be that Roche is looking
Premium ABN AMRO Biotechnology DNA
Patrick Roche‚ a YouTube famous slam poet‚ writes about his experiences with panic attacks. During the panic attacks‚ the body is in a specific state of mind: fight or flight mode. These responses his body is giving off makes him feel like he is dying. Roche’s Perfect Panic Attack slam poem is not about having a perfect panic attack but more about him showing the reality of his life in the moment of a panic attack. When the audience first sees the title of Roche’s poem‚ they interpret the perfect
Premium Eating disorders Bulimia nervosa Anorexia nervosa
Jun Sep Dec 2012 Roche GS‚ Price = 184.00 Roche B‚ Price = 186.90 Peer Set Index Patients on clinical trials Number of employees 4 1 CER: Constant exchange rates (average full-year 2011). 2 Proposed by the Board of Directors. 3 Prices translated at constant CHF exchange rates: USD=0.90; EUR=1.20; 100 JPY=1.10; GBP=1.40. 4 Full-time equivalents. 326‚642 82‚089 patients employees +10.4% +2.4% Key Events 2012 Roche Group 3% At the Roche Annual General Meeting in 2012
Free Cancer Breast cancer
development in every sector of the economy. Success lies in the ability to adapt with changing times. The Roche Group is a leading international healthcare company with principal businesses in pharmaceuticals‚ diagnostics and vitamins. The company is active in more than 150 countries and employs approximately 62‚000 people worldwide. The Roche corporate headquarters are in Basel‚ Switzerland. Roche is committed to improving healthcare by discovering‚ developing‚ manufacturing and providing pharmaceutical
Premium Pharmaceutical industry Marketing